“The vote language is front-page news and the clinical considerations don’t receive much attention.” — Matthew Daley, MD, of Kaiser Permanente Colorado, on ensuring risk mitigation strategies are communicated in language about COVID-19 booster shots at the CDC’s Advisory Committee on Immunization Practices meeting.

“I’d like to know what percentage of people in the United States have heard of the CDC.” — Paul Offit, MD, of Children’s Hospital of Philadelphia, discussing the news that CDC now reports COVID cases and deaths by vaccine status and whether it will sway the unvaccinated.

“Employers are trying to pretend they’re the victim in all this, but they’re not.” — Deborah Burger, RN, National Nurses United president, discussing nurse and other healthcare worker shortages at many medical centers.

“It takes time to gather that data, to know what titers people have and what their chance is of getting infected.” — Nathaniel (Ned) Landau, PhD, of NYU Grossman School of Medicine, on the lack of definitive data about what titer levels guarantee protection against COVID-19.

“But with no effectiveness, and certainly a risk of toxicity — and in several cases, severe toxicity — it’s not worth it.” — Robert Hendrickson, MD, of Oregon Health and Science University, about a report showing severe toxicity in some people who took ivermectin to prevent COVID-19.

Reference

Translate »